Feverfew extract found to be safe and effective in the prevention of migraine.
After taking the feverfew extract three times a day, by the third month those migraine patients who experienced an average of 4.76 attacks per month were only experiencing 2.86 attacks per month – a decrease of 1.9 monthly migraine attacks. Whereas those on placebo only experienced a 1.3 migraine per month decrease in monthly attack frequency.
Cephalalgia. 2005 Nov;25(11):1031-41.
Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention–a randomized, double-blind, multicentre, placebo-controlled study.
Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH.
Neurologische Universitätsklinik, Essen, Germany.
Summary of the abstract
The efficacy and tolerability of a CO(2)-extract of feverfew (MIG-99, 6.25 mg t.i.d.) for migraine prevention were investigated.
The primary endpoint was the average number of migraine attacks per 28 days during the treatment months 2 and 3 compared with baseline.
Safety parameters included adverse events, laboratory parameters, vital signs and physical examination.
The migraine frequency decreased from 4.76 by 1.9 attacks per month in the MIG-99 group and by 1.3 attacks in the placebo group.
MIG-99 is effective and shows a favourable benefit-risk ratio.